A Chemical Genomic Analysis of Decoquinate, a Plasmodium falciparum Cytochrome b Inhibitor

作者：Nam Tae gyu; McNamara Case W; Bopp Selina; Dharia Neekesh V; Meister Stephan; Bonamy Ghislain M C; Plouffe David M; Kato Nobutaka; McCormack Susan; Bursulaya Badry; Ke Hangjun; Vaidya Akhil B; Schultz Peter G^*; Winzeler Elizabeth A

来源：ACS Chemical Biology, 2011, 6(11): 1214-1222.

DOI：10.1021/cb200105d

Decoquinate has single-digit nanomolar activity against in vitro blood stage Plasmodium falciparum parasites, the causative agent of human malaria. In vitro evolution of decoquinate-resistant parasites and subsequent comparative genomic analysis to the drug sensitive parental strain revealed resistance was conferred by two nonsynonymous single nucleotide polymorphisms in the gene encoding cytochrome b. The resultant amino acid mutations, A122T and Y126C, reside within helix C in the ubiquinol-binding pocket of cytochrome b, an essential subunit of the cytochrome bc(1) Complex. As with other cytochrome bc(1) inhibitors, such as atovaquone, decoquinate has low nanomolar activity against in vitro liver stage P. yoelii and provides partial prophylaxis protection when administered to infected mice at 50 mg kg(-1). In addition, transgenic. parasites expressing yeast dihydroorotate dehydrogenase are >200 fold less sensitive to decoquinate, which provides additional evidence that this drug inhibits the parasite's mitochondrial electron transport chain Importantly, decoquinate exhibits limited cross resistance to a panel of atovaquone-resistant parasites evolved to harbor various mutations in-cytochrome b. The basis for this difference was revealed by molecular docking studies, in which both of these inhibitors were shown to have distinctly different modes of binding within the ubiquinol-binding site of cytochrome b.

• 出版日期2011-11